Gov't Shutdown Delays Merck's FDA Drug Hearing

Law360, New York (October 8, 2013, 7:00 PM EDT) -- In apparent fallout from the government shutdown, drugmakers Merck & Co. Inc. and Stallergenes on Tuesday announced that the U.S. Food and Drug Administration has postponed advisory committee meetings to discuss approving two prescription medicines, but the development is unlikely to herald more cancellations.

Both companies’ drugs are so-called allergenic extract products that are not covered by user-fee arrangements and therefore aren’t shielded from the shutdown’s effect on FDA, where roughly half the agency’s staffers have been furloughed.

An FDA document discussing effects of the shutdown...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.